Catalyst Pharmaceuticals Inc
CPRXHealthcare|Biotechnology|USA
$31.48
+0.00 (+0.00%)
DCF (FCF)
$21.18
Tangible Book
$7.29
Graham Number
$18.16
Earnings Power
$15.91
Clinical Trials (42)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05796570 A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies | Acute Myeloid Leukemia, Myelodysplastic Syndromes | P2 | Recruiting | 37 | Open-label | Decitabine, Filgrastim |
| NCT05556824 Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD | Gastroesophageal Reflux | P2 | Active | 247 | RCT, Double-blind | MHS-1031 |
| NCT07470853 A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | PROC, Platinum Resistant Ovarian Cancer | P1 | Recruiting | 265 | Open-label | HWK-016, MUCIN-16-targeted ADC, Bevacizumab |
| NCT06564974 Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | Duchenne Muscular Dystrophy | Recruiting | 250 | — | Vamorolone | |
| NCT02660645 Blue Light Cystoscopy With Cysview® Registry | Bladder Cancer | Recruiting | 4,400 | — | Hexaminolevulinate hydrochloride (HCL) | |
| NCT06989593 Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions | DSD, Hypospadias | N/A | Recruiting | 20 | Open-label | — |
| NCT02970162 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) | Lambert-Eaton Myasthenic Syndrome | P3 | Completed | 26 | RCT, Double-blind | Amifampridine Phosphate, Placebo Oral Tablet |
| NCT01377922 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) | Lambert Eaton Myasthenic Syndrome | P3 | Completed | 38 | RCT, Double-blind | Amifampridine Phosphate, Placebo |
| NCT02562066 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes | Myasthenic Syndromes, Congenital | P3 | Completed | 20 | RCT, Double-blind | amifampridine phosphate, Placebo |
| NCT03579966 Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) | Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | P3 | Terminated | 63 | Open-label | Amifampridine Phosphate |
| NCT03304054 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | Myasthenia Gravis, Generalized | P3 | Completed | 93 | RCT, Double-blind | Amifampridine Phosphate, Placebo Oral Tablet |
| NCT01281202 Vigabatrin for the Treatment of Cocaine Dependency | Cocaine Addiction, Cocaine Dependence | P2P3 | Completed | 207 | RCT, Double-blind | Vigabatrin, Matching Placebo |
| NCT04489537 Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | P3 | Terminated | 18 | RCT, Open-label | MarzAA |
| NCT05094401 Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes | Type2 Diabetes | P3 | Terminated | 76 | Open-label | — |
| NCT03781479 Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients | Muscular Atrophy, Spinal | P2 | Completed | 13 | RCT, Double-blind | Amifampridine Phosphate, Placebo Oral Tablet |
| NCT00730522 Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence | Methamphetamine Dependence | P2 | Terminated | 55 | RCT, Double-blind | CPP-109 vigabatrin, Matching Placebo |
| NCT00611130 Vigabatrin for Treatment of Cocaine Dependence | Cocaine Dependence | P2 | Completed | 186 | RCT, Double-blind | vigabatrin, placebo |
| NCT03819660 Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 | Spinal Muscular Atrophy Type 3 | P2 | Terminated | 13 | Open-label | Amifampridine Phosphate 10 MG Oral Tablet |
| NCT00527683 Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence | Cocaine Dependence | P2 | Completed | 100 | RCT, Double-blind | Vigabatrin, Placebo |
| NCT04920916 Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients | COVID-19 | P2 | Completed | 40 | RCT, Double-blind | Dupilumab, Placebo |
| NCT04548791 Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders | Factor VII Deficiency, Glanzmann Thrombasthenia | P1P2 | Terminated | 19 | Open-label | Coagulation Factor VIIa variant |
| NCT03407651 Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | P2 | Completed | 11 | Open-label | Coagulation Factor VIIa variant |
| NCT03995784 Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B | Hemophilia B | P2 | Completed | 6 | Open-label | Coagulation Factor IX variant, Coagulation Factor IX variant |
| NCT01493596 A Safety, Tolerability and Pharmacokinetic Study of CPP-115 | Cocaine Dependency | P1 | Completed | 55 | RCT, Double-blind | CPP-115, Placebo |
| NCT03186677 Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients | Hemophilia B | P1 | Completed | 11 | Open-label | ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg, BeneFIX |
| NCT04072237 Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia | Hemophilia A, Hemophilia B | P1 | Completed | 11 | Open-label | MarzAA (marzeptacog alfa [activated]) |
| NCT01439971 Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia | Hemophilia A | P1 | Completed | 29 | Open-label | PF-05280602, PF-05280602, PF-05280602, PF-05280602, PF-05280602 |
| NCT00830531 Pilot Study of Bumetanide for Newborn Seizures | Seizures | P1 | Completed | 43 | RCT, Double-blind | Bumetanide, Normal Saline as Placebo |
| NCT03062631 Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia | Congenital Myasthenic Syndrome | NO_LONGER_AVAILABLE | — | — | 3,4-Diaminopyridine | |
| NCT02189720 Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome | Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome | APPROVED_FOR_MARKETING | — | — | Amifampridine Phosphate | |
| NCT04968405 Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty | Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus | N/A | Completed | 87 | Open-label | — |
| NCT06106451 Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study) | Aortic Valve Disease, Aortic Valve Replacement | N/A | Completed | 40 | RCT, Single-blind | — |
| NCT05095623 A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease | Recurrent Bacterial Infection, Autoimmune Disorder | Terminated | 3 | — | — | |
| NCT02857972 Proof Of Concept Menstrual Hygiene Product-Wondaleaf® | Other Menstruation Disorders | N/A | Completed | 36 | Open-label | — |
| NCT04339296 Connected Healthcare for Individuals Living at Home With Chronic Conditions | Medication Adherence, Medication Compliance | N/A | Completed | 91 | RCT, Open-label | — |
| NCT06249529 Airway Bypass - Safety and Feasibility Study | Emphysema or COPD | Early P1 | Unknown | 10 | Open-label | — |
| NCT01015053 Postoperative Pain After Pediatric Umbilical Hernia Repair | Pediatric Postoperative Pain | N/A | Completed | 53 | RCT, Double-blind | — |
| NCT05072912 Screening Study to Identify Patients With Complement Factor I Deficiencies | Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency | Terminated | 113 | — | — | |
| NCT03324594 A Pilot Functional Performances Study of Two Synthetic Male Condom | Functional Performance, Synthetic Male Condom | N/A | Completed | 50 | RCT, Single-blind | — |
| NCT05569551 Umbilical Cord Care in Term Neonates: The Role of Wondaleaf Adhesive Pouch (WLAP) | Umbilical Cord Infection, Umbilical Sepsis | N/A | Completed | 218 | RCT, Double-blind | — |
| NCT02593214 Performance and Safety Trial of an Innovative Female Condom (Wondaleaf®) | Pregnancy, Sexually Transmitted Disease | N/A | Completed | 21 | Open-label | — |
| NCT04019795 Modulated Light Therapy in Participants With Pattern Hair Loss | Androgenetic Alopecia | N/A | Completed | 160 | RCT, Double-blind | — |